News Johnson & Johnson Swiss Exchange

Equities

JNJ

US4781601046

Market Closed - Swiss Exchange Other stock markets 09:06:28 25/05/2023 pm IST			After market 10:52:22 pm
136 ^USD	-0.73%		146.6	+7.82%

24/06	US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	RE
24/06	J&J: 50M pupils helped through 'Sight for Kids' program	CF

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	25/06	AQ
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	24/06	RE
J&J: 50M pupils helped through 'Sight for Kids' program	24/06	CF
Johnson & Johnson completes acquisition of Proteologix, Inc.	24/06	AQ
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	21/06	MT
Johnson & Johnson: filing in Crohn's disease	21/06	CF
Johnson & Johnson: acquisition of Proteologix completed	21/06	CF
Johnson & Johnson Completes Acquisition of Proteologix	21/06	MT
Johnson & Johnson Completes Acquisition of Proteologix	21/06	MT
Johnson & Johnson Completes Acquisition of Proteologix	21/06	MT
Johnson & Johnson Completes Acquisition of Proteologix, Inc.	21/06	BU
Health Authority Warns of Brain Risks From Pseudoephedrine Medications	21/06	AQ
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	21/06	CI
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	21/06	MT
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	21/06	PR
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	21/06	CI
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	20/06	BU
J&J: launches open, secure digital ecosystem	20/06	CF
J&J: promising results in Crohn's disease	20/06	CF
Johnson & Johnson Says Phase 3 Trial of Tremfya to Treat Crohn's Disease Met Co-Primary Endpoints	20/06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 11:00 pm IST